Agenus/LinkedIn
May 16, 2025, 02:44
Agenus will present new data from MSS metastatic colorectal cancer cohort at ESMO GI25
Agenus posted on LinkedIn:
“Agenus will present new data from its expanded MSS metastatic colorectal cancer cohort at ESMO GI25.
This poster will feature mature clinical outcomes, including durability of response and overall survival from the Phase 1 study of botensilimab and balstilimab.
Access full details.”
More posts featuring Agenus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 20:20
Jul 20, 2025, 20:10
Jul 20, 2025, 19:54
Jul 20, 2025, 19:20
Jul 20, 2025, 18:59
Jul 20, 2025, 18:27
Jul 20, 2025, 18:12
Jul 20, 2025, 17:37